GYRE
Price
$7.30
Change
-$0.17 (-2.28%)
Updated
Sep 23 closing price
Capitalization
663.04M
49 days until earnings call
RCKT
Price
$3.10
Change
-$0.08 (-2.52%)
Updated
Sep 23 closing price
Capitalization
334.5M
42 days until earnings call
Interact to see
Advertisement

GYRE vs RCKT

Header iconGYRE vs RCKT Comparison
Open Charts GYRE vs RCKTBanner chart's image
Gyre Therapeutics
Price$7.30
Change-$0.17 (-2.28%)
Volume$45.3K
Capitalization663.04M
Rocket Pharmaceuticals
Price$3.10
Change-$0.08 (-2.52%)
Volume$2.05M
Capitalization334.5M
GYRE vs RCKT Comparison Chart in %
Loading...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GYRE vs. RCKT commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GYRE is a Hold and RCKT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (GYRE: $7.30 vs. RCKT: $3.10)
Brand notoriety: GYRE and RCKT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GYRE: 47% vs. RCKT: 54%
Market capitalization -- GYRE: $663.04M vs. RCKT: $334.5M
GYRE [@Biotechnology] is valued at $663.04M. RCKT’s [@Biotechnology] market capitalization is $334.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GYRE’s FA Score shows that 1 FA rating(s) are green whileRCKT’s FA Score has 1 green FA rating(s).

  • GYRE’s FA Score: 1 green, 4 red.
  • RCKT’s FA Score: 1 green, 4 red.
According to our system of comparison, RCKT is a better buy in the long-term than GYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GYRE’s TA Score shows that 5 TA indicator(s) are bullish while RCKT’s TA Score has 3 bullish TA indicator(s).

  • GYRE’s TA Score: 5 bullish, 4 bearish.
  • RCKT’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, GYRE is a better buy in the short-term than RCKT.

Price Growth

GYRE (@Biotechnology) experienced а -3.82% price change this week, while RCKT (@Biotechnology) price change was -4.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.75%. For the same industry, the average monthly price growth was +7.78%, and the average quarterly price growth was +47.65%.

Reported Earning Dates

GYRE is expected to report earnings on Nov 12, 2025.

RCKT is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GYRE($663M) has a higher market cap than RCKT($335M). GYRE YTD gains are higher at: -39.669 vs. RCKT (-75.338). GYRE has higher annual earnings (EBITDA): 11.5M vs. RCKT (-245.09M). RCKT has more cash in the bank: 271M vs. GYRE (54.4M). GYRE has less debt than RCKT: GYRE (1.39M) vs RCKT (25.2M). GYRE has higher revenues than RCKT: GYRE (102M) vs RCKT (0).
GYRERCKTGYRE / RCKT
Capitalization663M335M198%
EBITDA11.5M-245.09M-5%
Gain YTD-39.669-75.33853%
P/E Ratio365.00N/A-
Revenue102M0-
Total Cash54.4M271M20%
Total Debt1.39M25.2M6%
FUNDAMENTALS RATINGS
GYRE vs RCKT: Fundamental Ratings
GYRE
RCKT
OUTLOOK RATING
1..100
622
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
14
Undervalued
PROFIT vs RISK RATING
1..100
90100
SMR RATING
1..100
8498
PRICE GROWTH RATING
1..100
8465
P/E GROWTH RATING
1..100
8100
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCKT's Valuation (14) in the Biotechnology industry is significantly better than the same rating for GYRE (92) in the null industry. This means that RCKT’s stock grew significantly faster than GYRE’s over the last 12 months.

GYRE's Profit vs Risk Rating (90) in the null industry is in the same range as RCKT (100) in the Biotechnology industry. This means that GYRE’s stock grew similarly to RCKT’s over the last 12 months.

GYRE's SMR Rating (84) in the null industry is in the same range as RCKT (98) in the Biotechnology industry. This means that GYRE’s stock grew similarly to RCKT’s over the last 12 months.

RCKT's Price Growth Rating (65) in the Biotechnology industry is in the same range as GYRE (84) in the null industry. This means that RCKT’s stock grew similarly to GYRE’s over the last 12 months.

GYRE's P/E Growth Rating (8) in the null industry is significantly better than the same rating for RCKT (100) in the Biotechnology industry. This means that GYRE’s stock grew significantly faster than RCKT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GYRERCKT
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 16 days ago
82%
Bullish Trend 8 days ago
79%
Declines
ODDS (%)
Bearish Trend 7 days ago
83%
Bearish Trend 15 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
82%
Aroon
ODDS (%)
Bullish Trend 1 day ago
76%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GLAXF20.330.41
+2.03%
GSK plc
BTURF0.51N/A
N/A
Bathurst Resources Ltd.
MCHVY23.31N/A
N/A
MGM China Holdings, Ltd.
OASMY0.02N/A
N/A
VIVESTO AB
INGEF3.41N/A
N/A
Ingenia Communities Group

GYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GYRE has been closely correlated with SPHDF. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if GYRE jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GYRE
1D Price
Change %
GYRE100%
-2.28%
SPHDF - GYRE
82%
Closely correlated
N/A
SPRC - GYRE
38%
Loosely correlated
+6.55%
BEAM - GYRE
36%
Loosely correlated
-2.79%
RCKT - GYRE
35%
Loosely correlated
-2.52%
VRDN - GYRE
33%
Poorly correlated
+0.05%
More

RCKT and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCKT has been loosely correlated with SVRA. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if RCKT jumps, then SVRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCKT
1D Price
Change %
RCKT100%
-2.52%
SVRA - RCKT
60%
Loosely correlated
-0.29%
PRTA - RCKT
51%
Loosely correlated
+0.24%
TECH - RCKT
42%
Loosely correlated
-0.23%
RGNX - RCKT
41%
Loosely correlated
-1.43%
ERAS - RCKT
40%
Loosely correlated
-0.56%
More